Immuneering Corp Income Statement
IMRX|3 years of annual SEC 10-K data (FY2021-FY2023)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Immuneering Corp reported $316,952 in revenue and $51M in net loss for FY2023. Revenue has declined at a 63.0% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Revenue | $317.0K | $2.1M | $2.3M |
| Cost of Revenue | $158.1K | $1.2M | $1.3M |
| Gross Profit | $158.8K | $926.9K | $1.0M |
| SG&A Expense | $15.6M | $8.3M | $3.1M |
| R&D Expense | $36.3M | $26.5M | $15.0M |
| Operating Income | -$51.7M | -$33.9M | -$17.1M |
| Income Tax | - | -$307.5K | -$307.5K |
| Net Income | -$50.5M | -$33.5M | -$17.0M |
| EPS (Basic) | -$1.91 | -$2.46 | -$3.44 |
| EPS (Diluted) | -$1.91 | -$2.46 | -$3.44 |
| Shares Outstanding | 26.4M | 13.6M | 5.0M |
| Gross Margin | 50.1% | 44.6% | 44.6% |
| Operating Margin | -16325.8% | -1629.2% | -739.0% |
| Profit Margin | -15937.3% | -1612.3% | -737.2% |